Loading…
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-64M | $-57M | $-56M | -29.2% | - | 28.8% |
| 2024 | $0M | $-49M | $-45M | $-36M | -26.7% | - | 10.3% |
| 2023 | $0M | $-43M | $-40M | $-38M | -59.2% | - | -38.7% |
| 2022 | $0M | $-65M | $-66M | $-27M | -64.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 37.54 | 43.61 | 49.15 | 64.55 |
| Research And Development | - | 16.81 | 24.99 | 31.70 | 42.63 |
| Selling General And Administration | - | 20.74 | 18.62 | 17.45 | 21.92 |
| Total Expenses | - | 37.54 | 43.61 | 49.15 | 64.55 |
| Operating Income | - | -37.54 | -43.61 | -49.15 | -64.55 |
| Total Operating Income As Reported | - | -67.06 | -43.61 | -49.15 | -64.55 |
| EBITDA | - | -64.57 | -43.27 | -48.82 | -64.19 |
| Normalized EBITDA | - | -35.07 | -43.28 | -48.86 | -64.24 |
| EBIT | - | -64.82 | -43.61 | -49.15 | -64.55 |
| Interest Income | - | 2.23 | 3.18 | 4.14 | 6.33 |
| Interest Expense | 1.74 | 1.14 | - | - | - |
| Net Interest Income | - | 1.09 | 3.18 | 4.14 | 6.33 |
| Other Non Operating Income Expenses | - | - | - | 0.39 | 0.73 |
| Other Income Expense | - | -29.50 | 0.01 | 0.42 | 0.78 |
| Interest Income Non Operating | - | 2.23 | 3.18 | 4.14 | 6.33 |
| Interest Expense Non Operating | 1.74 | 1.14 | - | - | - |
| Net Non Operating Interest Income Expense | - | 1.09 | 3.18 | 4.14 | 6.33 |
| Pretax Income | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income From Continuing And Discontinued Operation | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income From Continuing Operation Net Minority Interest | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income Common Stockholders | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income Including Noncontrolling Interests | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Normalized Income | - | -36.45 | -40.43 | -44.63 | -57.49 |
| Diluted NI Availto Com Stockholders | - | -65.95 | -40.42 | -44.60 | -57.44 |
| Basic Average Shares | 11.23 | 11.26 | 11.33 | 20.59 | - |
| Diluted Average Shares | 11.23 | 11.26 | 11.33 | 20.59 | - |
| Reconciled Depreciation | - | 0.25 | 0.34 | 0.33 | 0.36 |
| Total Unusual Items | - | -29.50 | 0.01 | 0.04 | 0.05 |
| Total Unusual Items Excluding Goodwill | - | -29.50 | 0.01 | 0.04 | 0.05 |
| Special Income Charges | 0 | -29.52 | 0 | - | - |
| Impairment Of Capital Assets | 0 | 29.52 | 0 | - | - |
| Gain On Sale Of Security | - | 0.02 | 0.01 | 0.04 | 0.05 |
| General And Administrative Expense | - | 20.74 | 18.62 | 17.45 | 21.92 |
| Other Gand A | - | 20.74 | 18.62 | 17.45 | 21.92 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Protara Therapeutics, Inc.this co. | TARA | $248M | -4.32 | 1.26 | -29.2% | -3.14 |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Nuvectis Pharma, Inc. | NVCT | $257M | -9.70 | 13.93 | -143.6% | - |
| Codexis, Inc. | CDXS | $255M |
| - |
| - |
| - |
| - |
| -5.79 |
| 5.04 |
| -87.0% |
| -8.18 |
| Sight Sciences, Inc. | SGHT | $250M | -6.51 | 3.91 | -60.1% | -6.07 |
| Coherus Oncology, Inc. | CHRS | $243M | 1.45 | 3.98 | 275.4% | -1.14 |
| Treace Medical Concepts, Inc. | TMCI | $239M | -4.06 | 2.74 | -67.6% | -6.98 |
| LifeMD, Inc. | LFMD | $236M | 16.41 | 10.17 | 62.0% | -135.17 |
| Peer Median | - | -4.92 | 4.51 | -62.9% | -6.07 | |